Hematologic Malignancies
Conference Coverage
ASCO honors Hagop Kantarjian, MD, for leukemia research
Noted Lebanese-American oncologist who leads the leukemia department at MD Anderson Cancer Center is to receive a top award at ASCO 2023.
News
What’s Causing Cancers at Air Force Bases?
News
CLL: Venetoclax combos top first-line chemoimmunotherapy
A triple-therapy combination yielded the best outcomes, but it should still be considered investigational.
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
News
“Terrific progress”: Adding blinatumomab for infant leukemia
Immunotherapy plus chemotherapy improves outcomes and may soon become first-line treatment for a rare pediatric blood cancer.
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
Conference Coverage
Relapsed CLL: New approaches prolong survival
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
Price of CLL Rx rises, despite competition
The cost of ibrutinib keeps going up, in spite of newer treatment options.
News
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
News
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.